90004-09-4

Usage

Uses

Used in Pharmaceutical Industry:
7-Amino-4(1H)-quinazolinone is used as a key intermediate in the synthesis of various pharmaceutical drugs for its potential therapeutic applications. Its unique chemical structure allows for the development of compounds with diverse biological activities, making it a valuable asset in drug discovery and medicinal chemistry.
Used in Anticancer Applications:
7-Amino-4(1H)-quinazolinone is employed as an anticancer agent, targeting various types of cancer cells. Its ability to inhibit the growth and proliferation of cancer cells, along with its potential to modulate multiple signaling pathways involved in cancer progression, makes it a promising candidate for cancer therapy.
Used in Anti-inflammatory Applications:
Due to its anti-inflammatory properties, 7-Amino-4(1H)-quinazolinone is used in the development of anti-inflammatory drugs. It can potentially alleviate inflammation and reduce the associated symptoms, offering a new avenue for the treatment of inflammatory disorders.
Used in Antioxidant Applications:
7-Amino-4(1H)-quinazolinone is utilized in the development of antioxidant agents, as it has demonstrated the ability to neutralize free radicals and protect cells from oxidative damage. This property makes it a potential candidate for the prevention and treatment of various diseases associated with oxidative stress.
Used in Medicinal Chemistry Research:
7-Amino-4(1H)-quinazolinone serves as an important compound in medicinal chemistry research, providing insights into the structure-activity relationships of quinazolinone derivatives. Its unique chemical properties and potential biological activities make it a valuable tool for understanding the mechanisms of action and optimizing the therapeutic potential of related compounds.

InChI:InChI=1/C8H7N3O/c9-5-1-2-6-7(3-5)10-4-11-8(6)12/h1-4H,9H2,(H,10,11,12)

Upstream product

• 619-17-0 4-Nitroanthranilic acid 
• 20872-93-9 4-hydroxy-7-nitroquinazoline 
• 20872-93-9 7-nitroquinazolin-4-one 
• 20872-93-9 7-nitroquinazolin-4(3H)-one 

Downstream Products

• 16064-25-8 7-hydroxyquinazolin-4-one 
• 202197-77-1 7-iodo-1H-quinazolin-4-one 
• 202197-79-3 (1-benzyl-1H-indazol-5-yl)-(7-iodoquinazolin-4-yl)-amine hydrochloride 
• 202197-78-2 4-chloro-7-iodoquinazoline 
• 887128-75-8 4-(4-oxo-3,4-dihydro-quinazolin-7-ylcarbamoyl)-4-phenyl-piperidine-1-carboxylic acid 9H-fluoren-9-ylmethyl ester 
• 887128-65-6 [3-(3,4-dichloro-phenyl)-3-(4-oxo-3,4-dihydro-quinazolin-7-ylcarbamoyl) propyl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Structure-based drug design, synthesis and screening of MmaA1 inhibitors as novel anti-TB agents

Abstract: Tuberculosis is one of the leading causes of death across the world. The treatment regimens for tuberculosis are well established, but still the control of the disease faces many challenges such as lengthy treatment protocols, drug resistance an

As neuroprotective agents of pharmaceutical compounds

The invention discloses a medicinal compound as a neuroprotective agent. The medicinal compound is a neuronal nitric oxide synthase-postsynaptic density protein 95 (nNOS-PSD95) decoupling agent. The medicinal compound is a benzene ring derivative shown in the general formula (I) or its pharmaceutically acceptable salt. The invention further discloses a preparation method of the medicinal compound and a use of the medicinal compound in prevention and treatment on neuronal damage influence-caused diseases.

Antiviral agents

This invention relates to compounds of formula I their salts, and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions comprising these compounds and their use in the treatment of picornavirus infections in mammals, as well as nove

Synthesis and SAR optimization of quinazolin-4(3H)-ones as poly(ADP-ribose)polymerase-1 inhibitors

We have demonstrated that quinazolin-4(3H)-one, a nicotinamide (NI) mimic with PARP-1 inhibitory activity in the high micromolar range (IC50 = 5.75 μM) could be transformed into highly active derivatives with only marginal increase in molecular weight. Convenient one to two synthetic steps allowed us to explore extensive SAR at the 2-, and 5- through 8-positions of the quinazolin-4(3H)-one scaffold. Substitutions at the 2- and 8-positions were found to be most favorable for improved PARP-1 inhibition. The amino group at 8-position resulted in compound 22 with an IC50 value of 0.76 μM. Combination of the 8-amino substituent with an additional methyl substituent at the 2-position provided the most potent compound 31 [8-amino-2-methylquinazolin- 4(3H)-one, IC50 = 0.4 μM] in the present study. Compound 31 inhibited the proliferation of Brca1-deficient cells with an IC50 value of 49.0 μM and displayed >10-fold selectivity over wild type counterparts. Binding models of these derivatives within the active site of PARP-1 have further supported the SAR data and will be useful for future lead optimization efforts.

Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account

Two closely related scaffolds were identified through an uHTS campaign as desirable starting points for the development of Rho-Kinase (ROCK) inhibitors. Here, we describe our hit-to-lead evaluation process which culminated in the rapid discovery of potent leads such as 22 which successfully demonstrated an early in vivo proof of concept for anti-hypertensive activity.

RHO KINASE INHIBITORS

Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including c

Antiviral agents

This invention relates to compounds of formula I their salts, and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions comprising these compounds and their use in the treatment of picornavirus infections in mammals as well as novel

Efficient synthesis of thiazoloquinazolinone derivatives

An original route to the rare 8H-thiazolo[5,4-f]quinazolin-9-one 1 and the novel 7H-thiazolo[4,5-h]quinazolin-6-one 2 is described. Access to the regioisomers was realized by fusion of a thiazole and a quinazoline ring via Appel's salt chemistry. Thermal